Background: Combination therapy with pegylated Interferon and Ribavirin is the best treatment for patients infected with hepatitis C virus (HCV), but it is only effective in half of patients. We recently demonstrated that USP18, the ISG15-specific protease, is important to HCV responses: it is one of the 18 gene signature predictive of response to therapy (Chen et al Gastroenterology 2005, 2010, and knockdown of USP18 increases the anti-HCV effect of IFNa (Randall et al Gastroenterology 2006). In this study we investigated how USP18 protease activity modulates HCV replication with and without IFNa. Methods: USP18 wild type (wt) and a protease-inactive mutant (USP18 C64S, mUSP18) expression constructs were cloned with an N-terminal GFP tag. Enzymatic activity of the expressed USP18 was confirmed by co-transfecting wtUSP18 or mUSP18 with plasmid DNA expressing ISG15-GST fusion protein. The effect of over-expression of wtUSP18 or mUSP18 on HCV RNA replication/viral particle secretion with or without IFNa was tested in the J6/JFH1 infectious culture system. Results: Over-expression of wtUSP18 in Huh7.5 cells led to decreased ISGylation in the presence of IFNa, an effect not seen with overexpression of mUSP18. Overexpression of both wtUSP18 and mUSP18 increased baseline HCV RNA replication and production of infectious virus by 4 5 fold; overexpression of both also blunted the anti-HCV effect of IFNa. Neither wtUSP18 nor mUSP18 inhibited the expression of common ISGs (MxA, ISG15, OAS2, Viperin) after exposure of Huh7.5 cells to IFNa. Conclusions: USP18 modulates HCV replication and the anti-HCV activity of IFNa independent of its protease activity and without disrupting IFNa signaling. These studies reveal that increased USP18 expression may be one way that HCV shelters itself from the host response, and should be considered a target for new anti-HCV therapies.
L. Chen 1 *, J. Sun 1 , J. Heathcote 1 , A. Edwards 1 , I. McGilvray 1 . 1 University of Toronto, Canada Background: Combination therapy with pegylated Interferon and Ribavirin is the best treatment for patients infected with hepatitis C virus (HCV), but it is only effective in half of patients. We recently demonstrated that USP18, the ISG15-specific protease, is important to HCV responses: it is one of the 18 gene signature predictive of response to therapy (Chen et al Gastroenterology 2005 , 2010 , and knockdown of USP18 increases the anti-HCV effect of IFNa (Randall et al Gastroenterology 2006) . In this study we investigated how USP18 protease activity modulates HCV replication with and without IFNa. Methods: USP18 wild type (wt) and a protease-inactive mutant (USP18 C64S, mUSP18) expression constructs were cloned with an N-terminal GFP tag. Enzymatic activity of the expressed USP18 was confirmed by co-transfecting wtUSP18 or mUSP18 with plasmid DNA expressing ISG15-GST fusion protein. The effect of over-expression of wtUSP18 or mUSP18 on HCV RNA replication/viral particle secretion with or without IFNa was tested in the J6/JFH1 infectious culture system. Results: Over-expression of wtUSP18 in Huh7.5 cells led to decreased ISGylation in the presence of IFNa, an effect not seen with overexpression of mUSP18. Overexpression of both wtUSP18 and mUSP18 increased baseline HCV RNA replication and production of infectious virus by 4 5 fold; overexpression of both also blunted the anti-HCV effect of IFNa. Neither wtUSP18 nor mUSP18 inhibited the expression of common ISGs (MxA, ISG15, OAS2, Viperin) after exposure of Huh7.5 cells to IFNa. Conclusions: USP18 modulates HCV replication and the anti-HCV activity of IFNa independent of its protease activity and without disrupting IFNa signaling. These studies reveal that increased USP18 expression may be one way that HCV shelters itself from the host response, and should be considered a target for new anti-HCV therapies.
OL-001 Association study of genetic variation in IL28B
with the hepatitis C treatment-induced viral clearance in Chinese Han population Background: Genome-wide association studies have recently confirmed the rs12979860 variation in IL28B is associated with the response to chronic hepatitis C (HCV) treatment. The aim of this study is to investigate whether the rs12979860 variation could be used as a predictive marker for end-of-treatment response (ETR) or sustained virological response (SVR) in Chinese Han population. Methods: Totally, 259 HCV infected individuals were detected the rs12979860 genotypes by DNA sequencing. Among them, 120 patients with complete pegylated interferon Alfa and ribavirin combination therapy and 92 patients followed for 24 weeks after the cessation of treatment were divided into different groups according to outcomes of treatment.
Results: The rs12979860 CC genotype was the main genotype in Chinese Han patients (87.64%, 227/259) and only one TT genotype was found in this cohort of patients. The patients with rs12979860 CC genotype got higher rates of ETR (P = 0.0044) and SVR (P = 0.0046) than the patients with N-CC (CT, TT) genotypes. In multiple logistic-regression models, the rs12979860 variation was associated with a more substantial difference in rates of achieving ETR To promote the diagnostic rate of HIV/AIDS complicated with cytomegalovirus (CMV) viremia, enhance curative effects and improve the prognosis. The clinical data in 249 cases of HIV/AIDS patients hospitalized from Oct.2008 to Nov. 2009 have been collected and studied retrospectively, in which we found that 43 HIV/AIDS patients have infected CMV. Pathological detections have been analyzed from specimen taken with gastroscope, fibercoloscope, bronchoscope and bronchoalveolar lavage fluid (BALF). We also analyzed association between cellular immunity and CMV-DNA levels. We found that 43 patients (17.3%) have been diagnosed as CMV viremia in accordance with positive results of CMV pp65 antigen and CMV-DNA; 14 patients manifested Background: HIV-1 genotypic-resistance is becoming increasingly significant in drug resistance monitoring. However, many areas in some developing countries in Asia still lack of such information due to its high running cost. This is the first study to determine the prevalence of drug resistance mutations of reverse transcriptase (RT) and protease (PR) genes and specific HIV-1 subtypes in Northeastern part of Malaysia. Methods: The genotypic resistance testing was performed among 50 HIV-1 seropositive treated and treatment naïve subjects in Hospital Raja Perempuan Zainab 2, Kota Bharu. The HIV-1 PR and RT genes were amplified from 140 ml of plasma-derived HIV-1 viral RNA via reverse transcriptionpolymerase chain reaction and genotype determined via DNA sequencing. Drug resistance mutations were analysed using the Stanford HIV Sequence Resistance Database.
Results: CRF01_AE was found to be the dominant subtype by both PR and RT genes in both antiretroviral treated and naive patients (59.4%). B subtype was present to a much lower level (21.9%), followed by CRF01_AE/B intersubtype recombinant (18.8%). Fifteen percent of the treated and 0.06% naïve patients had mutations associated with PIs. The frequency of mutations associated with NRTIs and NNRTIs resistance in treated patients was 40.6% and 34.4%, respectively compared to 0.06% and 0.09% in naïve patients.
